Tevogen Bio Holdings Inc
For the period ended Dec 31, 2023. Filed Apr 29, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Apr 29, 2024
TVGN$5.84+4.5%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Statements of Cash Flows
| For the Year Ended December 31, | For the Year Ended December 31, | |
|---|---|---|
| 2023 | 2022 | |
| Cash Flows from Operating Activities: | ||
| Net (loss) income | $(67,325) | $4,408,361 |
| Adjustments to reconcile net (loss) income to net cash used in operating activities: | ||
| Unrealized gain on investments held in Trust Account | (2,734,426) | (4,948,194) |
| Non-cash interest expense | 256,031 | — |
| Impairment of amount due from related party | 250,000 | |
| Change in fair value of warrants | 21,750 | (413,250) |
| Changes in operating assets and liabilities: | ||
| Prepaid expenses and other assets | 142,669 | 446,609 |
| Due from related party | (267,000) | — |
| Due to affiliate | 90,000 | 120,000 |
| Accounts payable and accrued expenses | 931,950 | 171,079 |
| Net cash used in operating activities | (1,376,351) | (215,395) |
| Cash Flows from Investing Activities: | ||
| Extension amount deposited into Trust Account | (67,500) | — |
| Cash withdrawn from Trust Account in connection with redemption | 342,984,430 | — |
| Net cash provided by investing activities | 342,916,930 | — |
| Cash Flows from Financing Activities: | ||
| Proceeds from note payable | 1,323,500 | — |
| Redemption of ordinary shares | (342,984,430) | — |
| Net cash used in financing activities | (341,660,930) | — |
| Net Change in Cash | (120,351) | (215,395) |
| Cash – Beginning | 129,186 | 344,581 |
| Cash – Ending | $8,835 | $129,186 |
| Supplemental disclosure of noncash activities: | ||
| Change in value of Class A ordinary shares subject to redemption amount | $2,801,927 | $4,964,000 |
| Sale of Class B shares to Investor | $3,955,111 | $— |
| Sale of warrants | $20,000 | $— |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.